Remission of Cushing's disease with growth hormone replacement

Lindholm, 2001, Incidence and late prognosis of Cushing's syndrome:a opulation-based study, Clin. Endocrinol. Metab., 86, 117 Newell-Price, 2006, Cushing's syndrome, Lancet, 367, 1605, 10.1016/S0140-6736(06)68699-6 Porpiglia, 2004, Bilateral adrenalectomy for Cushing's syndrome: a comparison between laparoscopy and open surgery, J. Endocrinol. Invest., 27, 654, 10.1007/BF03347498 Sheehan, 2000, Radiosurgery for Cushing's disease after failed transsphenoidal surgery, J. Neurosurg., 93, 738, 10.3171/jns.2000.93.5.0738 Miller, 1993, The medical treatment of Cushing's syndrome, Endocr. Rev., 14, 443, 10.1210/edrv-14-4-443 Praw, 2009, Medical treatment of Cushing's disease: Overview and recent findings, Int. J. Gen. Med., 29, 209 Carroll, 2004, Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion, Clin. Endocrinol. (Oxf), 60, 169, 10.1046/j.1365-2265.2003.01922.x Johannsson, 2004, Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease, Clin. Endocrinol. (Oxf), 60, 550, 10.1111/j.1365-2265.2004.02018.x Feldt-Rasmussen, 2002, Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease, Eur. J. Endocrinol., 146, 167, 10.1530/eje.0.1460067 Hughes, 1999, Growth hormone status following treatment for Cushing's syndrome, Clin. Endocrinol. (Oxf), 51, 61, 10.1046/j.1365-2265.1999.00738.x Nieman, 2002, Medical therapy of Cushing's disease, Pituitary, 5, 77, 10.1023/A:1022308429992 Ranjan, 2010, Efficacy of Cabergoline in Uncured Cushing's disease (Persistent/Recurrent) After Pituitary Surgery +/− Radiotherapy, Endocr. Pract., 24, 1 Pivonello, 2007 Pivonello, 2009, The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery, J. Clin. Endocrinol. Metab., 94, 223, 10.1210/jc.2008-1533 Boscaro, 2009, Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial, J. Clin. Endocrinol. Metab., 94, 115, 10.1210/jc.2008-1008 Ambrosi, 2004, Effects of chronic administration of PPARgamma ligand rosiglitazone in Cushing's disease, Eur. J. Endocrinol., 151, 173, 10.1530/eje.0.1510173 Pecori Giraldi, 2007, Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease, Eur. J. Endocrinol., 156, 233, 10.1530/eje.1.02329 Paulsen, 2006, Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue, J. Clin. Endocrinol. Metab., 91, 1093, 10.1210/jc.2005-1694 Tomlinson, 2003, Low-dose growth hormone inhibits 11_-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity, J. Clin. Endocrinol. Metab., 88, 2113, 10.1210/jc.2002-021894 Gelding, 1998, The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11_-hydroxysteroid dehydrogenase activity, Clin. Endocrinol. (Oxf), 48, 153, 10.1046/j.1365-2265.1998.3641180.x Kotelevtsev, 1997, 11_-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress, Proc. Natl. Acad. Sci. U. S. A, 94, 14924, 10.1073/pnas.94.26.14924 Yau, 2007, Enhanced hippocampal long-term potentiation and spatial learning in aged 11beta-hydroxysteroid dehydrogenase type 1 knock-out mice, J. Neurosci., 26;27, 10487, 10.1523/JNEUROSCI.2190-07.2007 Wake, 2003, Local and systemic impact of transcriptional up-regulation of 11_-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity, J. Clin. Endocrinol. Metab., 88, 3983, 10.1210/jc.2003-030286 Stewart, 1998, Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle, J. Clin. Invest., 82, 340, 10.1172/JCI113592 Tschöp, 2000, Effects of growth hormone replacement therapy on levels of cortisol and cortisol-binding globulin in hypopituitary adults, Eur. J. Endocrinol., 143, 769, 10.1530/eje.0.1430769 Webb, 2010, Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma, J. Clin. Endocrinol. Metab., 95, 630, 10.1210/jc.2009-0806